Isolation and identification of a novel phage targeting clinical multidrug-resistant Corynebacterium striatum

Jiao Wang1, Meng Zhang1, Jiao Pei2

  • 1Department of Pathogen Biology, School of Basic Medicine, Hubei University of Arts and Science, Xiangyang, China.

Abstract

Insights

Researchers discovered CSP1, a novel bacteriophage effective against multidrug-resistant Corynebacterium striatum (MDR-C. striatum). This finding offers a promising new avenue for bacteriophage therapy and combating superbug infections in healthcare settings.

Area of Science:

  • Microbiology
  • Virology
  • Infectious Diseases

Background:

  • Corynebacterium striatum (C. striatum) is an emerging multidrug-resistant (MDR) pathogen causing significant healthcare challenges, particularly in immunocompromised individuals.
  • The increasing prevalence of MDR pathogens necessitates the development of novel therapeutic strategies.

Purpose of the Study:

  • To isolate and characterize bacteriophages capable of targeting multidrug-resistant Corynebacterium striatum (MDR-C. striatum).
  • To evaluate the potential of identified bacteriophages for therapeutic applications against C. striatum infections.

Main Methods:

  • Screening of bacteriophages from environmental samples (restroom puddles) against 54 clinical MDR-C. striatum isolates.
  • Purification, genome extraction, sequencing, and characterization of the isolated bacteriophage CSP1.
  • Assays included Dot Plaque, Double-layer plate, one-step growth curves, transmission electron microscopy, and stability tests (temperature, pH, salinity).

Main Results:

  • A novel temperate bacteriophage, CSP1, was identified with a 39,752 bp double-stranded DNA genome, classified as a new species within the Caudoviricetes class.
  • CSP1 demonstrated a broad host range, infecting and lysing 21 clinical MDR-C. striatum isolates.
  • The bacteriophage exhibited stability across a wide range of temperatures (-40 to 55°C), pH (4 to 12), and salinity, with no observed cytotoxicity.

Conclusions:

  • CSP1 is the first identified phage targeting clinical Corynebacterium striatum strains.
  • This discovery presents significant potential for bacteriophage therapy development against MDR-C. striatum.
  • The findings pave the way for novel diagnostic and therapeutic tools to combat pathogenic bacteria.